ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,639, issued on Nov. 4, was assigned to BeyondSpring Pharmaceuticals Inc. (New York).
"Tubulin binding compounds and therapeutic use thereof" was invented by Lan Huang (New York), Santosh Ambadas Khedkar (Lexington, Mass.) and Michel O. Steinmetz (Villigen, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed."
The patent was filed on April 24, 2023, under Application No. 18/306,191.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Par...